Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Combined With TACE in Advanced Intrahepatic Cholangiocarcinoma
NCT04954781Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Primary endpoint: Objective Response Rate. Started Jul 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04954781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954781.